Retrospective Analysis of Cancer-Associated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort by András, Csilla et al.
ORIGINAL ARTICLE
Retrospective Analysis of Cancer-Associated Myositis Patients
over the Past 3 Decades in a Hungarian Myositis Cohort
Csilla András1 & Levente Bodoki2 & Melinda Nagy-Vincze3 & Zoltán Griger3 & Emese Csiki1 & Katalin Dankó3
Received: 17 May 2019 /Accepted: 1 October 2019
# The Author(s) 2019
Abstract
Association between cancer and myositis has been extensively reported and malignancy is a potentially life-threating complica-
tion in myositis. In this retrospective study authors give an overview of Hungarian cancer-associated myositis (CAM) patients
treated at a single centre managing 450 myositis patients. All patients were diagnosed according to Bohan and Peter. Statistical
analysis of disease onset, age, sex, muscle, skin and extramuscular symptoms, muscle enzymes, presence of antibodies, treatment
and prognosis was performed. 43 patients could be considered as having CAM. 83.72% had cancer within one year of diagnosis
of myositis. Most common localizations were ductal carcinoma of breast and adenocarcinoma of lung. Significant differences
were observed between CAM and the non-CAM control patients: DM:PM ratio was 2.31:1 vs. 0.87:1, respectively (p = 0.029),
age at diagnosis was 56.60 ± 12.79 vs. 38.88 ± 10.88 years, respectively (p < 0.001). Tumour-treatment was the following:
surgical removal in 55.81%, chemotherapy in 51.1%, radiotherapy in 39.53%, hormone treatment in 18.6%, combination therapy
in 51.16% of patients. Muscle enzyme levels of patients undergoing surgery were significantly reduced after intervention. 36
patients died (83.72%); 25 DM (83.33%) and 11 PM patients (84.62%); 5 years survival was 15.4% for PM and 27.5% for DM.
This study demonstrates that DM, distal muscle weakness, asymmetric Raynaud’s phenomenon, older age, ANA-negativity are
risk factors for developing malignancy and polymyositis patients have less chance of long-lasting survival. It is very important to
think about cancer and follow every single myositis patient in the clinical routine because survival rate of CAM is very poor.
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Introduction
Idiopathic inflammatory myopathies (IIMs) are systemic,
chronic, autoimmune diseases, characterised by symmetrical,
proximal muscle weakness. The IIMs fall into six clinico-
pathological categories: (1) dermatomyositis (DM; juvenile,
adult), (2) polymyositis (PM), (3) overlap syndromes (OM),
(4) cancer-associated myositis (CAM), (5) inclusion body
myositis (IBM), and (6) focal and diffuse myositis, including
necrotizing autoimmune myopathy (NAM) [1–11]. The link
between myositis and cancer was originally noticed in the
early 1900’s [12], also by Bohan and Peter in their classifica-
tion in 1975 [13], and has been than proved by large
population-based studies [14]. Modern epidemiologic works
have provided strong support for this association and evidence
that it may also be true for PM, but the risk is lower than that
for DM patients [15]. This well-recognised association be-
tween IIM and malignancy is a remarkable complication con-
tributing to increased mortality in myositis. While the exact
pathogenesis of CAM remains unclear, a paraneoplastic na-
ture was assumed in the majority of these patients because
cancer diagnosis and myositis onset seemed to temporally
coincide [16]. The discovery of myositis-associated antibod-
ies (MAAs) and myositis-specific antibodies (MSAs) led to
the development of the clinico-serological classification and
the recently discovered anti-TIF1gamma antibodies seem to
be strong related to malignancy [17, 18]. The recent publica-
tion of the European League Against Rheumatism and
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American College of Rheumatology (EULAR/ACR) classifi-
cation criteria for IIM [19, 20] was a big step forward because
it makes the everyday work of the physician easier. Despite its
many advantages this classification criteria does not contain
any specific factor that can help in the recognition of CAM
patients. There is limited evidence for specific treatment strat-
egies in IIM and this also applies for CAM [21]. It is still of
primary importance to diagnose these complicated cases as
early as possible because the possibility of survival increases
with early identification and therapy.
Aims
In this retrospective study authors aimed to give a retrospec-
tive overview of Hungarian myositis patients with malignancy
treated at a single centre. At the Division of Clinical
Immunology, Department of Medicine, University of
Debrecen, Hungary, 450 myositis patients have been treated
since the end of the 1980’s, 304 patients with PM, OM, IBM
or NAM and 146 patients with DM. Our aim was to study the
clinical, immunological and therapeutic characteristics of
myositis cases associated with cancer from the last 3 decades.
Methods
Data Collection
We retrospectively collected data from the University’s com-
puterized patient record system, called eMedSolution. All se-
lected myositis patients had a definitive or probable diagnosis
for myositis (muscle weakness, high muscle enzyme levels,
plus positive EMG and / or positive muscle biopsy in poly-
myositis or skin symptoms in dermatomyositis, according to
Bohan and Peter). No juvenile DM/PM cases were selected.
All myositis patients that had cancer during their life were
primarily enrolled to the study. Based on these, 60 cases could
be identified. Analysis of following epidemiologic, clinical,
laboratory and therapeutic data were performed: age, sex,
muscle symptoms, skin symptoms, extramuscular symptoms,
serum level of creatine kinase, lactate dehydrogenase, pres-
ence or absence of MSAs or MAAs, drugs used for the treat-
ment of cancer and myositis, and prognosis of patients.
Detection of Antibodies
Immunoserological analyses, which were performed at the
Department of Laboratory Medicine, University of
Debrecen, included tests for the following autoantibodies.
Antinuclear antibodies (ANA) were determined by indirect
immunofluorescence on HEp-2 cells (Viro-Immun
Labordiagnostika GmbH, Oberursel, Deutschland); ANA
positivity was assessed at 1:40 dilution. Anti-Scl70, anti-Sm/
RNP were determined in all patients by ELISA (Hycor
Biomedical Inc., Garden Grove, CA, USA). Anti-Jo-1, anti-
Mi-2, anti-Pm-Scl, anti-Ku antibodies were detected by
membrane-fixed immuno-blot (Orgentec Diagnostika
GmbH, Mainz, Deutschland). Anti-SSA and anti-SSB were
determined by ELISA (Hycor Biomedical Inc., Garden
Grove, CA, USA), as well as anti-U1RNP (Orgentec
Diagnostica GmbH,Mainz, Deutschland). These commercial-
ly available methods were used following the manufacturer’s
protocol.
Diagnosis of Clinical Parameters, Muscular
and Internal Organ Involvement
EMGwas performed using the Buchtal-method at Department
of Neurology, University of Debrecen. Muscle biopsies were
performed by surgeons and analysed by a neuropathologist.
Pulmonary fibrosis was defined as present by radiographic
findings and pulmonary function tests (spirometry, DLCO).
Dysphagia was diagnosed by barium radiography of the oe-
sophagus. Cardiac involvement was encoded in case of peri-
carditis, myocarditis, conduction disturbances, myocardial is-
chemia and recurrent arrhythmia; it was assessed by ECG,
two-dimensional and Doppler echocardiography. Imaging
studies (US, X-ray, CT, HRCT, MRI, PET-scan) were done,
if needed, at the Department of Radiology, University of
Debrecen.
Statistics
To compare groups with categorical data Pearson Chi-square
(χ2) test was used. To compare groups with small number of
cases Fisher’s exact test was used. Statistical analysis was
made using SPSS 20.0 statistical software. When creating a
small group of patients as control group random number gen-
erator had been used. During statistical analysis, the P value
less than 0.05 was regarded as statistically significant.
Results
There are no clear literature data on when to consider a case as
a CAM patient because the exact characteristics of the timely
association of malignant disease and myositis are not known.
Based on the previous work of our group [22] plus relying on
data from other population studies [23], we evaluated the
myositis as „tumour associated^ in the following cases: 1. if
the tumour was diagnosed within two years before muscle
symptoms; 2. if the cancer process has been diagnosed within
three years after the onset of myositis symptoms. Accordingly,
out of a total of 60 patients who have ever had cancer, a total
of 43 patients could be considered as having CAM (Fig. 1.).
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Hereinafter we deal with these 43 patients. In seven patients
symptoms of myositis and cancer appeared simultaneously
(±3 months); in another 29 patients cancer was diagnosed
±1 year of myositis onset. This means that 83.72% of all
patients had cancer within one year of the diagnosis of myo-
sitis. DM:PM ratio was 2.31:1, with 30 DM and 13 PM pa-
tients. Age at the diagnosis of CAM was 56.60 ± 12.79
(55.9 ± 13.71 for DM and 58.23 ± 10.71 for PM patients).
Female:male ratio was 2.07:1, with 29 women and 14 men,
for DM patients 2.33:1 and for PM patients 1.6:1.
In our opinion it is important to know when these cases
were diagnosed. If we divided the 29 years between 1990 and
2018 into 5-year periods, the number of patients in each time
interval was as follows: 1990–1994: one patient, 1995–1999:
six, 2000–2004: twelve, 2005–2009: thirteen, 2010–2014:
nine, 2015-nowadays: two patients.
One of the most important questions is the type of cancers
that were associated to the myositis. These data can be follow-
ed on Table 1. The twomost common anatomical localizations
were breast and lung while the most common histological
types were ductal carcinoma of the breast and adenocarcinoma
in different localizations.
To compare some of the most important characteristics of
CAM patients and Bsimple^ myositis patients we generated a
control group. Between 1990 and 2018, we also created six
B5-year intervals^. Out of the 390 non-CAM patients, 43 pa-
tients were randomly selected using a computer (random num-
ber generator); there were as many patients in each interval as
it was by the CAM group, representing the whole non-cancer
associated myositis population. In this group, no patient had
ever malignancy. The DM:PM ratio was 0.87:1. Age at diag-
nosis of myositis was 38.88 ± 10.88, female:male ratio was
2.31:1 with 30 women and 13 men. These data are summa-
rized in Table 2. We can see that there was a significant dif-
ference between the two groups in the case of the DM:PM
ratio and the disease onset. Most important clinical, serologi-
cal and therapeutic data of these two groups are summarized
and compared in Table 3.
Some notable results of symptoms in the CAM group were
for example the relative high number of distal muscle weak-
ness. We underline the clinical importance of skin symptoms
in the patients associated with cancer. Most important
extramuscular manifestations in the CAM group were joint
involvement and oesophagus involvement. Only 18.6% and
23.26% of patients with CAM had any MSAs or MAAs. All
patients received steroids but other immunosuppressant drugs
were not widely used in this group of patients.
Another interesting question is to explain what levels of
muscle enzymes have occurred in our patients. In CAM pa-
tients, at onset of muscle symptoms, the mean value of crea-
tine kinase levels was 3269.34 ± 4306.35 IU/L (2715.95 ±
3564.52 IU/L for DM and 4078.15 ± 5238 IU/L for PM pa-
tients), and the mean value of lactate dehydrogenase was
1019 ± 760.69 IU/L (1096.67 ± 752.07 IU/L for DM and
894.31 ± 788.16 IU/L for PM patients). In the control group,
at onset of muscle symptoms, these mean values were
4543.16 ± 4542.09 IU/L for CK and 1248.58 ± 3222.55 IU/L
for LDH (statistically significant higher than those in CAM
patients: p values 0.048 and 0.021, respectively). CK and
LDH of patients undergoing surgery were significantly re-
duced after intervention. CK just before surgery was
4297.20 ± 5584.24 IU/L and after surgery was 1144.43 ±
887.82 IU/L (p = 0.006); LDH right before surgery was
1126.38 ± 828.61 IU/L and after surgery was 653.19 ±
620.82 (p = 0.027).
We should also mention the oncological treatment of
these 43 patients. In 24 cases (55.81%) surgical removal
of the tumour occurred, 22 patients (51.1%) received
chemotherapy, 17 patients (39.53%) received radiothera-
py, 8 patients (18.6%) got hormone treatment, 5 extreme-
ly serious cases (11.62%) did not receive any anti-
tumour treatment. A total of 22 patients (51.16%) re-
ceived combination therapy (two, three or four types of
treatment).
This question leads us to another important issue:
survival of CAM patients. All together 36 of the 43
Fig. 1 43 patients had CAM of
the myositis population
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patients died (83.72%); 25 DM (83.33%) and 11 PM
patients (84.62%). According to the statistical analysis
the mean survival for the 43 CAM patients were 54.85
(29.44–80.26; 95% CI) months, the survival rates at one
and at five years from diagnosis were 55.5% and
23.4%, respectively. These data for the 30 DM patients
out of the 43 CAM patients are: mean survival 57.55
(25.06–89.04; 95% CI) months, the survival rates at one
and at five years from diagnosis were 49.4% and
27.5%, respectively. The appropriate data for the
13 PM patients out of the 43 CAM patients are: mean
survival 37.85 (18.83–56.86; 95% CI) months, the sur-
vival rates at one and at five years from diagnosis were
69.2% and only 15.4%, respectively. Survival rates can
be followed on Fig. 2. Median survival of the 43 CAM
patients were 16.00 (4.54–24.46; 95% CI) months. As
mentioned earlier, the disease was extremely fulminant
in five patients. In four cases 2–5 months after severe
myositis symptoms, lung cancer was confirmed. Their
survival was only 1–2 months after the diagnosis of
the tumour; in their case, the cause of death was the
following: respiratory failure due to respiratory muscle
involvement; severe bronchitis; pneumonia; progression
of the tumour process due to brain metastases. In an-
other case, severe DM symptoms were associated with
metastatic pancreatic cancer, and the patient died of liv-
er failure. Cause of death of other CAM patients, apart
from the above mentioned, were among others ileus,
renal failure, tumour progression, metastases or sepsis.
Discussion
Our department has decades of experience in the field of
healing of patients with myositis. After 29 years of follow-up,
we believe that it can be stated that cancer cases occurring two
years before or three years after the diagnosis of myositis can be
considered as CAM. In this study, more than 80% of the cancers
were diagnosed within one year of onset of muscle symptoms
which means that it is very important to think about the possi-
bility of cancer at every single myositis patient. Out of the 450
myositis patients there were 43 CAM patients (9.56%); this
means that one in every ten myositis patient is a CAM patient.
In an Italian cohort it was 17% [23]. In our whole myositis
population there were 30 DM-CAM (out of 146 patients;
20.55%) and 13 PM-CAM (out of 304 patients; 4.28%) pa-
tients. This reflects that: both DM and PM are associated with
increased risk of malignancy but dermatomyositis is more as-
sociated with any type of cancer than polymyositis. This is
similar to the results of other workgroups [24]. In a study from
northern China, the frequency of malignancy in DM patients
was 17.99%, similar as our result [25]. Some other interesting
data of this Chinese cohort also should be discussed here.
69.77% of malignancy was diagnosed within the first year be-
fore or after the onset of myositis; this is a little bit lower than
our result. The most frequent histology was adenocarcinoma
but they found that lung cancer was the most frequent
localisation. According to the most recent demographic data
of the cancer registries (2006–2015) in Hungary the lung
(males) and breast (females) cancers are at first place in
Table 1 Types of malignancy in
our CAM patients Number of patients Localisation of cancer Type of cancer
15 breast ductal carcinoma (14)
lobular invasive carcinoma (1)
12 lungs adenocarcinoma (4)
squamous cell carcinoma (2)
small-cell carcinoma (2)
not known (4)
3 mouth cavity squamous cell carcinoma of the epipharynx (2)
mucoepidermoid carcinoma of the salivary glands (1)
2 colon adenocarcinoma
2 ovary cystadenocarcinoma




1 urinary bladder carcinoma transitiocellulare
1 penis squamous cell carcinoma
1 prostate adenocarcinoma
1 brain ependymoma
1 cervix uteri cystadenocarcinoma
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cancer-morbidity hierarchy [26]. This is in harmony with our
results. Just like us, other workgroups also detected other
atypical types of tumour-localisation in CAM patients: ovarian
cancer [27], colorectal cancer [28], haematological malignancy
Table 2 Important demographic
data of CAM patients and Bnon-
malignancy^ patients
CAM patients Myositis patients with no malignancy P value
Number of patients 43 43
DM:PM ratio 2.31:1 0.87:1 0.029
Age at disease onset 56.6 ± 12.79 38.88 ± 10.88 0.001
Female:male ratio 2.07:1 2.33:1 0.816
Table 3 Comparison of CAM




malignancy (n = 43)
P value
Skin symptoms
Proximal muscle weakness 43 43 1
Distal muscle weakness 7 0 0.012
Gottron’s papules 24 14 0.03
Gottron’s sign 15 11 0.348
Heliotrop rash 18 15 0.506
V-sign 22 10 0.007
Periungual teleangiectasia 10 4 0.08
Mechanics’ hand 5 5 1
Other clinical signs
Raynaud’s phenomenon 7 15 0.048
Arthralgia/arthritis 20 29 0.05
Fever at disease onset 2 0 0.494
Interstitial lung disease 6 7 0.763
Dysphagia 17 20 0.514
Heart involvement 3 3 1
Autoantibodies
ANF 12 28 0.001
Anti-Mi-2 2 9 0.024
Anti-SRP 3 1 0.616
Anti-Jo-1 3 0 0.241
Anti-PL-7 0 0 –
Anti-PL-12 0 0 –
Anti-SSA 5 5 1
Anti-SSB 2 2 1
Anti-Sm-RNP 2 2 1
Anti-PM-Scl 0 1 1
Anti-Ku 1 0 1
Anti-U1RNP 0 0 –
Anti-Scl-70 0 1 1
Therapy
Steroids 43 42 1
Methotrexate 5 15 0.011
Azathioprine 5 15 0.011
Cyclophosphamide 4 10 0.08
Cyclosporine A 4 18 0.001
IVIG 2 7 0.156
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[29], cervical cancer [30], pancreatic tumour [31], carcinoma of
the penis [32] or prostate cancer [33].
Comparing the CAM patients to the control group, as seen
in Table 2., older age can be a risk factor for malignancy in
myositis patients. 56.6 years at disease onset is the same as
found by Sellami et al. in 2018 [34]. In our studied population
there was no significant difference in female:male ratio. In
contrast, a meta-analysis from China found that male sex in-
creases the risk of malignancy [35]. As seen in Table 3., the
frequency of ANF positivity in CAM patients was statistically
significant lower than in patients without malignancy. The
same result was concluded by Hoesly et al. in their study in
2018 [36]. Skin symptoms were more frequent in the CAM
group this is because DM:PM ratio was significantly higher in
these patients. There is data in the international literature that
distal muscle weakness is more frequent in malignancy-
associated cases; 16.28% of this group had this kind of muscle
symptom and this is a significant difference between the two
groups. Perhaps it also can be a warning sign for cancer. The
frequency of Raynaud’s phenomenon was significantly lower
in the malignancy-related group. In a high percentage of cases
it was asymmetric and that can be the first sign of malignancy
[37]. There was no significant difference between the two
populations in the frequency of extramuscular manifestations
(arthralgia, dysphagia, heart involvement and lung fibrosis). A
meta-analysis found that malignancy was associated with a
reduced risk of developing ILD [38]. Another systemic review
said that several factors were associated with lower risk of
malignancy, including the presence of ILD, arthritis/
arthralgia or anti-Jo-1 antibody [39]. As seen in Table 3., we
cannot strengthen these data. But Lu et al., as well as our
workgroup, found that the Raynaud’s phenomenon is associ-
ated with lower-than-average risk for malignancy [39].
Despite anti-tumour therapy, survival rate of our CAM pa-
tients was very poor. The survival rate of primary PM and DM
group at 5 years was significantly higher (100% and 100%),
compared with the CAM-patient group, where survival was
15.4% for PM and 27.5% for DM. Although the risk in PM
patients is lower to have cancer, there is less chance of long-
lasting survival. Neri et al. found that the chance of long-
lasting survival is higher in PM patients [23]. Regarding
anti-myositis therapy immunosuppressant drugs were less fre-
quently used in CAM patients than in simple myositis pa-
tients. Despite the widely studied association between myosi-
tis and cancer the best strategy for diagnosing and treat cancer
in IIM patients is lacking [40].
Conclusion
Authors underline the clinical importance of the fast diagnosis
and the best possible therapy in patients with cancer-
associated myositis. According to the results of this retrospec-
tive review the risk of malignancy is present in both genders
and higher age groups and is highest in the first year before or
after onset of myositis. Patients with DM have a higher inci-
dence of malignancy than patients with PM and both groups
have a poor prognosis. Adults should be evaluated for malig-
nancy at diagnosis, followed by long-term surveillance.
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